Ex vivo cultures of glioblastoma in three-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening

Experimental Cell Research

Volumn 321, Issue 2, 2014, Pages 99-108

  Jiguet Jiglaire, Carine ^a,b,c   Baeza Kallee, Nathalie ^a,b,c   Denicolaï, Emilie ^a,b,c   Barets, Doriane ^a,b,c   Metellus, Philippe ^a,b,c,d   Padovani, Laetitia ^a,b,c,d   Chinot, Olivier ^a,b,c,d   Figarella Branger, Dominique ^a,b,c,d   Fernandez, Carla ^a,b,c,d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b University of the Mediterranean Aix Marseille II   (France)

^c INSERM   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

3D environment; Glioblastoma; Preclinical tool; Sensitivity screening

Indexed keywords

CARMUSTINE; CISPLATIN; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CELL FUNCTION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; DRUG SCREENING; EX VIVO STUDY; GLIOBLASTOMA; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEL; IN VITRO STUDY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; THREE DIMENSIONAL HYDROGEL; TREATMENT RESPONSE; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT;

3D ENVIRONMENT; GLIOBLASTOMA; PRECLINICAL TOOL; SENSITIVITY SCREENING;

ANIMALS; CELL PROLIFERATION; CELL SHAPE; DRUG EVALUATION, PRECLINICAL; GLIOBLASTOMA; HUMANS; HYDROGEL; MICE; MICE, NUDE; PRIMARY CELL CULTURE; RADIATION TOLERANCE; TISSUE SCAFFOLDS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895059534     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.12.010     Document Type: Article

References (21)

1. Chinot O.L., Barrie M., Fuentes S., Eudes N., Lancelot S., Metellus P., Muracciole X., Braguer D., Ouafik L., Martin P.M., Dufour H., Figarella-Branger D. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J. Clin. Oncol. 2007, 25:1470-1475.
2. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
3. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
4. Vaira V., Fedele G., Pyne S., Fasoli E., Zadra G., Bailey D., Snyder E., Faversani A., Coggi G., Flavin R., Bosari S., Loda M. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl. Acad. Sci. USA 2010, 107:8352-8356.
5. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
6. Cunha G.R., Hayward S.W., Wang Y.Z., Ricke W.A. Role of the stromal microenvironment in carcinogenesis of the prostate. Int. J. Cancer 2003, 107:1-10.
7. Ananthanarayanan B., Kim Y., Kumar S. Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform. Biomaterials 2011, 32:7913-7923.
8. Biggs T., Foreman J., Sundstrom L., Regenass U., Lehembre F. Antitumor compound testing in glioblastoma organotypic brain cultures. J. Biomol. Screen. 2011, 16:805-817.
9. Gal H., Makovitzki A., Amariglio N., Rechavi G., Ram Z., Givol D. A rapid assay for drug sensitivity of glioblastoma stem cells. Biochem. Biophys. Res. Commun. 2007, 358:908-913.
10. Shimizu F., Hovinga K.E., Metzner M., Soulet D., Tabar V. Organotypic explant culture of glioblastoma multiforme and subsequent single-cell suspension. Curr. Protocols Stem Cell Biol. 2011, Unit 3.5. (Chapter 3).
11. Metellus P., Coulibaly B., Nanni I., Fina F., Eudes N., Giorgi R., Barrie M., Chinot O., Fuentes S., Dufour H., Ouafik L., Figarella-Branger D. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 2009, 115:4783-4794.
12. Widschwendter M., Siegmund K.D., Muller H.M., Fiegl H., Marth C., Muller-Holzner E., Jones P.A., Laird P.W. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004, 64:3807-3813.
13. Ashley D.M., Riffkin C.D., Lovric M.M., Mikeska T., Dobrovic A., Maxwell J.A., Friedman H.S., Drummond K.J., Kaye A.H., Gan H.K., Johns T.G., Hawkins C.J. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br. J. Cancer 2008, 99:294-304.
14. Ruoslahti E. Brain extracellular matrix. Glycobiology 1996, 6:489-492.
15. Nirmalanandhan V.S., Duren A., Hendricks P., Vielhauer G., Sittampalam G.S. Activity of anticancer agents in a three-dimensional cell culture model. Assay Drug Dev. Technol. 2010, 8:581-590.
16. Ono A., Kanno H., Hayashi A., Nishimura S., Kyuma Y., Sato H., Ito S., Shimizu N., Chang C.C., Gondo G., Yamamoto I., Sasaki T., Tanaka M. Collagen gel matrix assay as an in vitro chemosensitivity test for malignant astrocytic tumors. Int. J. Clin. Oncol. 2007, 12:125-130.
17. Iwadate Y., Fujimoto S., Namba H., Yamaura A. Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing. Br. J. Cancer 2003, 89:1896-1900.
18. Colman H., Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Arch. Neurol. 2008, 65:877-883.
19. Thomas D.G., Darling J.L., Paul E.A., Mott T.J., Godlee J.N., Tobias J.S., Capra L.G., Collins C.D., Mooney C., Bozek T., et al. Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma. Br. J. Cancer 1985, 51:525-532.
20. Rosenblum M.L., Gerosa M.A., Wilson C.B., Barger G.R., Pertuiset B.F., de Tribolet N., Dougherty D.V. Stem cell studies of human malignant brain tumors. Part 1: development of the stem cell assay and its potential. J. Neurosurg. 1983, 58:170-176.
21. Kimmel D.W., Shapiro J.R., Shapiro W.R. In vitro drug sensitivity testing in human gliomas. J. Neurosurg. 1987, 66:161-171.